• Company
• K-botulinum products are expanding globally
• by Jun 22, 2022 05:59am

• Policy
• The benefit discussion for Steglatro was excluded
• by Lee, Tak-Sun Jun 22, 2022 05:58am

• Policy
• Report of severe skin SE such as rash of Phenytoin
• by Lee, Hye-Kyung Jun 21, 2022 05:55am

• InterView
• “Roche reborn through customer-centric reorganization”
• by Eo, Yun-Ho Jun 21, 2022 05:54am

• Company
• Takeda Korea appoints Sun Jin Lee as head of Oncology BU
• by Jun 21, 2022 05:54am

• Company
• KIMS has signed a license agreement for Lipothasone
• by Nho, Byung Chul Jun 21, 2022 05:54am

• Policy
• The HIRA launched a benefit review for Tabrecta
• by Lee, Tak-Sun Jun 21, 2022 05:54am

• Policy
• Drug price cut refund bill’s fate depends on LJC Chair
• by Lee, Jeong-Hwan Jun 20, 2022 06:04am

• Company
• 11 of the national essential drugs are non reimbursed
• by Eo, Yun-Ho Jun 20, 2022 06:04am

• Company
• TNBC will be added to Keytruda's indications
• by Eo, Yun-Ho Jun 20, 2022 06:04am